[{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"HTL Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Liniment","sponsorNew":"HTL Biotechnology \/ Eirion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"HTL Biotechnology \/ Eirion Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by HTL Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Botulinum Toxin A

                          Therapeutic Area : Dermatology

                          Study Phase : Phase II

                          Sponsor : Eirion Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Details : As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axi...

                          Product Name : ET-01

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          August 09, 2021

                          Lead Product(s) : Botulinum Toxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Eirion Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          HTL Biotechnology Biopolymer